Key Performance
More- Earnings Score: 55
- Momentum Score: 28
- True Yield: 87
- Financial Health Score: 0
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A class action lawsuit has been filed against Zoetis Inc. alleging securities fraud for making materially false and misleading statements about its Companion Animal segment products. The complaint claims the company failed to disclose weakening veterinarian adoption of Librela due to FDA safety warnings, significant market share losses for Simparica Trio to lower-priced competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 are eligible to join the class action, with a lead plaintiff deadline of July 27, 2026.
06/22/2026, 12:00 PM • GlobeNewswire
Rosen Law Firm reminds investors in Zoetis Inc. (ZTS) of the July 27, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Zoetis made false statements about market share growth and product adoption during the period from February 14, 2025 to May 6, 2026. Specifically, the firm claims Zoetis failed to disclose weakening demand for its Librella pain treatment due to FDA safety warnings, loss of market share for Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint.
06/19/2026, 3:53 PM • GlobeNewswire
A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products during January 14, 2025 to May 6, 2026. The lawsuit claims the company failed to disclose weakening veterinarian adoption of its Librela pain treatment following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. Investors with losses exceeding $100,000 are encouraged to join the class action before the July 27, 2026 lead plaintiff deadline.
06/19/2026, 2:14 PM • GlobeNewswire
A class action lawsuit has been filed against Zoetis, Inc. for allegedly making materially false statements and failing to disclose material adverse facts about its business. The complaint alleges that Zoetis concealed weakening veterinarian adoption of its Librela product following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 have until July 27, 2026 to apply as lead plaintiff.
06/18/2026, 3:40 PM • GlobeNewswire
The global Veterinary API Manufacturing Market is projected to grow from USD 7.21 billion in 2025 to USD 18.48 billion by 2035, driven by rising zoonotic disease prevention efforts, increasing pet ownership, and expanding animal healthcare investments. The market is segmented by service type, synthesis type, therapeutic category, and animal type, with North America and Asia-Pacific leading regional growth.
06/18/2026, 11:00 AM • GlobeNewswire
Rosen Law Firm is notifying investors in Roblox Corporation, Zoetis Inc., and Barclays PLC of ongoing securities class action lawsuits. The firm is seeking lead plaintiffs with an August 7, 2026 deadline. The Roblox case alleges the company made false statements about organic growth potential while concealing material adverse facts about enrollment verification impacts.
06/16/2026, 6:30 PM • GlobeNewswire
Zoetis Inc. faces a securities class action lawsuit alleging the company misled investors about its Companion Animal portfolio's competitive strength and growth prospects. The stock collapsed 21.5% ($23.91 per share) after four corrective disclosures revealed that key products like Librela, Simparica Trio, and Apoquel/Cytopoint underperformed projections due to safety concerns, intensified competition, and declining veterinarian confidence. The lead plaintiff deadline is July 27, 2026, and the class period covers January 14, 2025 to May 6, 2026.
06/15/2026, 3:55 PM • GlobeNewswire
A class action lawsuit has been filed against Zoetis Inc. alleging securities fraud for making false statements about product growth and market positioning in its Companion Animal segment. The complaint claims the company failed to disclose weakening adoption of Librela due to FDA safety warnings, significant market share losses for Simparica Trio and dermatology products Apoquel and Cytopoint to competitors. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 are encouraged to join the case.
06/15/2026, 12:00 PM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits on behalf of investors in GRAIL, Inc. and other companies. The GRAIL lawsuit alleges that defendants made materially false and misleading statements regarding the NHS-Galleri trial results, concealing that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. Investors who purchased GRAIL stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The lead plaintiff deadline is August 4, 2026.
06/13/2026, 9:29 PM • GlobeNewswire
Rosen Law Firm is encouraging investors who purchased Zoetis Inc. securities between January 14, 2025 and May 6, 2026 to join a class action lawsuit. The lawsuit alleges that Zoetis made false statements about market share and sales growth while failing to disclose weakening adoption of key products like Librela due to FDA safety warnings, market share losses in Simparica Trio and dermatology products, and declining veterinarian adoption. The lead plaintiff deadline is July 27, 2026.
06/13/2026, 9:28 PM • GlobeNewswire
Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies. Calix faces allegations of misleading statements regarding margin pressures from memory component costs. AeroVironment is accused of overstating business prospects amid competitive threats. Zoetis is alleged to have concealed weakening demand for key products due to safety concerns and market competition. Lucid Group is charged with failing to disclose supplier quality issues affecting vehicle deliveries. All cases have lead plaintiff deadlines in late July 2026.
06/11/2026, 12:00 PM • GlobeNewswire
A securities class action lawsuit has been filed against Zoetis Inc. for allegedly making false and misleading statements about its Companion Animal products. The lawsuit claims the company failed to disclose weakening veterinarian adoption of Librela due to FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share in dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 may be entitled to compensation. The lead plaintiff deadline is July 27, 2026.
06/10/2026, 4:47 PM • GlobeNewswire
Class action lawsuits have been filed against Calix, AeroVironment, and Zoetis for allegedly making false or misleading statements about their financial performance and business prospects. Investors have until July 27, 2026 to file lead plaintiff motions in these securities fraud cases.
06/05/2026, 1:33 PM • GlobeNewswire
Rosen Law Firm has filed class action lawsuits against Zoetis Inc., Babcock & Wilcox Enterprises, and Stellantis N.V. on behalf of investors who purchased securities during specified periods. The Zoetis lawsuit alleges the company made false statements about market share and product adoption while failing to disclose weakening sales of key products including Librela, Simparica Trio, and dermatology treatments due to safety concerns and increased competition. Investors are encouraged to secure counsel before the July 27, 2026 deadline to serve as lead plaintiff.
06/04/2026, 6:48 PM • GlobeNewswire
A class action lawsuit has been filed against Zoetis Inc. alleging that the company made materially false and misleading statements about its Companion Animal segment products. The complaint claims Zoetis failed to disclose weakening veterinarian adoption of Librela due to FDA safety warnings, significant market share losses of Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 are encouraged to join the lawsuit, with a lead plaintiff deadline of July 27, 2026.
06/04/2026, 12:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.